GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Decipher Labs Ltd (BOM:524752) » Definitions » Debt-to-EBITDA

Decipher Labs (BOM:524752) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 1995. Start your Free Trial

What is Decipher Labs Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Decipher Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Decipher Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹0.0 Mil. Decipher Labs's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹5.2 Mil. Decipher Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Decipher Labs's Debt-to-EBITDA or its related term are showing as below:

BOM:524752' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.85   Med: 0.6   Max: 4.11
Current: -0.17

During the past 13 years, the highest Debt-to-EBITDA Ratio of Decipher Labs was 4.11. The lowest was -0.85. And the median was 0.60.

BOM:524752's Debt-to-EBITDA is ranked worse than
100% of 660 companies
in the Drug Manufacturers industry
Industry Median: 1.67 vs BOM:524752: -0.17

Decipher Labs Debt-to-EBITDA Historical Data

The historical data trend for Decipher Labs's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Decipher Labs Debt-to-EBITDA Chart

Decipher Labs Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.46 4.11 4.00 0.75 -0.29

Decipher Labs Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.06 - - -

Competitive Comparison of Decipher Labs's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Decipher Labs's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Decipher Labs's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Decipher Labs's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Decipher Labs's Debt-to-EBITDA falls into.



Decipher Labs Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Decipher Labs's Debt-to-EBITDA for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(9.494 + 0) / -33.049
=-0.29

Decipher Labs's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Decipher Labs  (BOM:524752) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Decipher Labs Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Decipher Labs's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Decipher Labs (BOM:524752) Business Description

Traded in Other Exchanges
N/A
Address
Road No. 2, 4th Floor, Plot No. 94, Sagar Society, Banjara Hills, Hyderabad, TG, IND, 500034
Decipher Labs Ltd, formerly Combat Drugs Ltd is an India-based company engaged in the trading and manufacturing of Pharmaceutical drugs. It also undertakes contract manufacturing services business. The group generates revenue from the sale of its pharmaceutical products.

Decipher Labs (BOM:524752) Headlines

No Headlines